Edinburgh Research Explorer

ITI Techmedia Biosensing Platform

Project: Research

StatusFinished
Effective start/end date1/10/0530/09/10
Total award£353,511.00
Funding organisationUK industry, commerce and public corporations
Funder project referenceITI-No Reference
Total award£358,648.00
Funding organisationUK industry, commerce and public corporations
Funder project referenceITI-No Reference
Total award£391,300.00
Funding organisationUK industry, commerce and public corporations
Funder project referenceITI-No Reference
Period1/10/0530/09/10

Description

Working in an emerging technology area, known as ‘theranostics’, the proposed solution combines diagnostic data and therapeutic solutions to tailor treatments for individual patients.
The technology aims to reduce the cost and complexity of disease diagnosis and treatment in the clinical environment, and will offer the ability to manage both disease progression and drug therapy effects. Theranostic solutions are already in use in the treatment of breast cancer where therapy can be determined by performing specific tests. The development of this technology platform could see similar solutions becoming mainstream for a range of diseases.
In the initial stages, ITI Techmedia has engaged the services of four organisations to carry out the work involved in the early research and system design phase of the programme. The team includes the following partners.
The University of Edinburgh's contributhin involves an interdiscipliary team from the GTI, Physics, Chemistry and Engineering i, with expertise in the application and development of sensors, microsystems and custom and high density bioarray / microarray platforms
Axis-Shield is a UK/Norwegian company headquartered in Scotland that develops and globally markets diagnostic tests and systems for use both in laboratory and point of care. . Lab901 is a Scottish company, focused on the laboratory automation market by integrating established molecular biology procedures with novel miniaturisation and automation techniques. Haptogen is pioneering a novel approach, focusing know-how and patent-protected technology on developing antibodies against bioactive haptens.